GSK Korea said Monday that it has appointed Rob Kempton, a healthcare expert with more than 20 years of service in the U.S., the U.K. and Asia, as its new chief executive officer effective on Dec. 1.

GSK Korea has appointed Rob Kempton as its new CEO. (GSK Korea)
GSK Korea has appointed Rob Kempton as its new CEO. (GSK Korea)

New CEO Kempton has contributed significantly to the U.S. launch of Trelegy, combination therapy for chronic obstructive pulmonary disease (COPD), it said.

Kempton, an expert in infectious, respiratory and neurological diseases, joined GSK in 2013 and served as head of sales management in the U.S. branch of ViiV Healthcare, GSK's HIV-specialized subsidiary. He also served as a general sales manager in charge of marketing in Dolutegravir in the U.S.

Kempton most recently served as vice president of overseas sales for GSK's follow-up pipeline.

"I am very honored and excited to be appointed to lead GSK Korea," Kempton said. "Based on the company's achievements so far, GSK Korea aims to establish itself as a leading pharmaceutical and vaccine company in Korea."

The company will do its best to attain sustainable business growth with competent executives and employees to help patients lead healthier and more energetic lives, Kempton added.

Copyright © KBR Unauthorized reproduction, redistribution prohibited